{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Target+Lesion&page=15",
    "query": {
      "condition": "Target Lesion",
      "page": 15
    },
    "page_size": 10
  },
  "pagination": {
    "page": 15,
    "page_size": 10,
    "total_count": 515,
    "total_pages": 52,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Target+Lesion&page=16&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Target+Lesion&page=14&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T09:59:50.505Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02374021",
      "title": "Treatments Against RA and Effect on FDG-PET/CT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Arthritis, Rheumatoid"
      ],
      "interventions": [
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Sulfasalazine",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "Etanercept",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 159,
      "start_date": "2016-07",
      "completion_date": "2021-05",
      "has_results": true,
      "last_update_posted_date": "2022-10-26",
      "last_synced_at": "2026-10-25T09:59:50.505Z",
      "location_count": 31,
      "location_summary": "Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 25 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Murrieta",
          "state": "California"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02374021"
    },
    {
      "nct_id": "NCT04971733",
      "title": "A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "E2814",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 8,
      "start_date": "2021-06-28",
      "completion_date": "2024-05-24",
      "has_results": true,
      "last_update_posted_date": "2025-06-10",
      "last_synced_at": "2026-10-25T09:59:50.505Z",
      "location_count": 2,
      "location_summary": "La Jolla, California • Indianapolis, Indiana",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04971733"
    },
    {
      "nct_id": "NCT06376877",
      "title": "Connectomic Targeted TMS Target for Refractory Anxiety",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anxiety Disorders",
        "Mental Disorder",
        "Psychiatric Disorder"
      ],
      "interventions": [
        {
          "name": "Transcranial magnetic stimulation",
          "type": "PROCEDURE"
        },
        {
          "name": "Sham transcranial magnetic stimulation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 80,
      "start_date": "2024-08-01",
      "completion_date": "2029-02-01",
      "has_results": false,
      "last_update_posted_date": "2024-04-19",
      "last_synced_at": "2026-10-25T09:59:50.505Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06376877"
    },
    {
      "nct_id": "NCT00842283",
      "title": "Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Dermatologic Diseases"
      ],
      "interventions": [
        {
          "name": "skin tissue sample",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2008-11",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-10-25T09:59:50.505Z",
      "location_count": 2,
      "location_summary": "Irvine, California",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00842283"
    },
    {
      "nct_id": "NCT05064553",
      "title": "ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hepatocellular Carcinoma",
        "Hepatocellular Cancer",
        "Hepatitis B",
        "Cirrhosis",
        "Liver Cancer"
      ],
      "interventions": [
        {
          "name": "Study CT/MRI Imaging",
          "type": "DEVICE"
        },
        {
          "name": "Standard of Care CT/MRI Imaging",
          "type": "DEVICE"
        },
        {
          "name": "Oncoguard™ Liver Test",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Exact Sciences Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2990,
      "start_date": "2021-07-26",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-10-15",
      "last_synced_at": "2026-10-25T09:59:50.505Z",
      "location_count": 76,
      "location_summary": "Chandler, Arizona • Sun City, Arizona • Bakersfield, California + 62 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05064553"
    },
    {
      "nct_id": "NCT04875702",
      "title": "Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Gout"
      ],
      "interventions": [
        {
          "name": "Allopurinol",
          "type": "DRUG"
        },
        {
          "name": "Naproxen 250 MG",
          "type": "DRUG"
        },
        {
          "name": "Colchicine 0.6 mg",
          "type": "DRUG"
        },
        {
          "name": "Colchicine 1.2 mg",
          "type": "DRUG"
        },
        {
          "name": "Naproxen 500 Mg",
          "type": "DRUG"
        },
        {
          "name": "Prednisone 40 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 650,
      "start_date": "2024-02-22",
      "completion_date": "2028-10-31",
      "has_results": false,
      "last_update_posted_date": "2025-09-25",
      "last_synced_at": "2026-10-25T09:59:50.505Z",
      "location_count": 7,
      "location_summary": "South Birmingham, Alabama • Santa Monica, California • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "South Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04875702"
    },
    {
      "nct_id": "NCT00790400",
      "title": "Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Tuberous Sclerosis Complex (TSC)",
        "Lymphangioleiomyomatosis (LAM)"
      ],
      "interventions": [
        {
          "name": "Everolimus (RAD001)",
          "type": "DRUG"
        },
        {
          "name": "Everolimus Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 118,
      "start_date": "2009-04",
      "completion_date": "2015-11",
      "has_results": true,
      "last_update_posted_date": "2017-02-17",
      "last_synced_at": "2026-10-25T09:59:50.505Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00790400"
    },
    {
      "nct_id": "NCT03261050",
      "title": "Target Engagement of a Novel Dissonance-Based Treatment for DSM-5 Eating Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Eating Disorder"
      ],
      "interventions": [
        {
          "name": "Counter Attitudinal Therapy",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Interpersonal Therapy",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "34 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 34 Years · Female only"
      },
      "enrollment_count": 83,
      "start_date": "2017-07-10",
      "completion_date": "2025-01-31",
      "has_results": false,
      "last_update_posted_date": "2025-06-11",
      "last_synced_at": "2026-10-25T09:59:50.505Z",
      "location_count": 2,
      "location_summary": "Stanford, California • Eugene, Oregon",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Eugene",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03261050"
    },
    {
      "nct_id": "NCT03724097",
      "title": "Identification of Molecular Biomarkers for Cancer Target Therapy Efficacy",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "RNA sequencing",
          "type": "OTHER"
        },
        {
          "name": "Transcriptome analysis",
          "type": "OTHER"
        },
        {
          "name": "target drug with the score above 0,1",
          "type": "DRUG"
        },
        {
          "name": "target drug with the score equal or below 0,1",
          "type": "DRUG"
        },
        {
          "name": "non-target drug",
          "type": "DRUG"
        },
        {
          "name": "palliative care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "OmicsWay Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 200,
      "start_date": "2017-10-17",
      "completion_date": "2022-11-01",
      "has_results": false,
      "last_update_posted_date": "2021-09-14",
      "last_synced_at": "2026-10-25T09:59:50.505Z",
      "location_count": 1,
      "location_summary": "Walnut, California",
      "locations": [
        {
          "city": "Walnut",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03724097"
    },
    {
      "nct_id": "NCT04857697",
      "title": "Effects of Probiotics on the Gut Microbiome and Immune System in Operable Stage I-III Breast or Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Anatomic Stage I Breast Cancer AJCC v8",
        "Anatomic Stage II Breast Cancer AJCC v8",
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Breast Adenocarcinoma",
        "Stage I Lung Cancer AJCC v8",
        "Stage II Lung Cancer AJCC v8",
        "Stage III Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Probiotic",
          "type": "DRUG"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2021-07-01",
      "completion_date": "2023-03-08",
      "has_results": false,
      "last_update_posted_date": "2023-04-21",
      "last_synced_at": "2026-10-25T09:59:50.505Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04857697"
    }
  ]
}